China approves first drug for mild to moderate Alzheimer's in 17 years

4 November 2019 – Chinese Pharmaceutical Company Green Valley announced over the weekend that their drug Oligomannate (GV-971) has been granted conditional approval by the National Medical Products Administration (NMPA) as a new drug for the treatment of “mild to moderate Alzheimer's disease and improving cognitive function”. [read more]

Biogen and Eisai announce plans to file for market approval of Alzheimer's drug

22 October 2019 – Biogen and Eisai today announced that they will file for market approval for the drug aducanumab, an investigational treatment for early Alzheimer’s disease, following new analysis showing reduced clinical decline in people with early Alzheimer’s disease. [read more]

Dementia given high priority at G20 Health Ministers Meeting

21 October 2019 – Following advocacy by ADI and its members, dementia was given high priority in the Okayama Declaration of the G20 Health Ministers, displaying an ongoing commitment of the G20 to addressing the biggest health and social care crisis of the 21st century. [read more]

Spanish government launches national plan to tackle dementia

15 October 2019 – It was today announced by the Spanish Ministry of Health, Consumption and Social Welfare that they had adopted a national dementia plan. The National Alzheimer's Plan 2019-2023 will be a crucial support for the Spanish population affected by dementia now and in the future. [read more]

Syndicate content